{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:32:55Z","timestamp":1792510375151,"version":"4.5.0"},"reference-count":59,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"published-print":{"date-parts":[[2021,1,15]]},"DOI":"10.18632\/aging.202232","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T15:37:50Z","timestamp":1607009870000},"page":"1051-1070","source":"Crossref","is-referenced-by-count":13,"title":["Targeting nerve growth factor, a new option for treatment of osteoarthritis: a network meta-analysis of comparative efficacy and safety with traditional drugs"],"prefix":"10.18632","volume":"13","author":[{"given":"Ziqin","family":"Cao","sequence":"first","affiliation":[{"name":"Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeling","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, University of California, Davis, CA 95817, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingquan","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of General Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanchun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2020,12,3]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/art.41142","article-title":"2019 American college of rheumatology\/arthritis foundation guideline for the management of osteoarthritis of the hand, hip, and knee.","volume":"7","author":"Hawker","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2","doi-asserted-by":"publisher","first-page":"d1165","DOI":"10.1136\/bmj.d1165","article-title":"All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study.","volume":"34","author":"J\u00fcni","year":"2011","journal-title":"BMJ"},{"key":"3","volume-title":"Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research.","author":"Institute of Medicine (US) Committee on Advancing Pain Research, Care, and Education","year":"2011"},{"key":"4","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/S0140-6736(14)60802-3","article-title":"Osteoarthritis.","volume":"38","author":"Carr","year":"2015","journal-title":"Lancet"},{"key":"5","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1126\/science.3306916","article-title":"The nerve growth factor 35 years later.","volume":"23","author":"Levi-Montalcini","year":"1987","journal-title":"Science"},{"key":"6","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0166-2236(96)10058-8","article-title":"Nerve growth factor: from neurotrophin to neurokine.","volume":"1","author":"Leon","year":"1996","journal-title":"Trends Neurosci"},{"key":"7","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.pain.2013.04.035","article-title":"A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee.","volume":"15","author":"West","year":"2013","journal-title":"Pain"},{"key":"8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1001\/jama.2019.8044","article-title":"Effect of tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis among patients with osteoarthritis of the hip or knee: a randomized clinical trial.","volume":"32","author":"Verburg","year":"2019","journal-title":"JAMA"},{"key":"9","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/ijcp.12807","article-title":"Efficacy and safety of fulranumab as monotherapy in patients with moderate to severe, chronic knee pain of primary osteoarthritis: a randomised, placebo- and active-controlled trial.","volume":"7","author":"Thipphawong","year":"2016","journal-title":"Int J Clin Pract"},{"key":"10","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.3899\/jrheum.131294","article-title":"Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen.","volume":"4","author":"Verburg","year":"2014","journal-title":"J Rheumatol"},{"key":"11","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.pain.2014.03.018","article-title":"Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee.","volume":"15","author":"Mellis","year":"2014","journal-title":"Pain"},{"key":"12","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.joca.2011.09.006","article-title":"Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study.","volume":"1","author":"Muto","year":"2011","journal-title":"Osteoarthritis Cartilage"},{"key":"13","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1056\/NEJMoa0901510","article-title":"Tanezumab for the treatment of pain from osteoarthritis of the knee.","volume":"36","author":"Brown","year":"2010","journal-title":"N Engl J Med"},{"key":"14","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1002\/art.37950","article-title":"Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial.","volume":"6","author":"West","year":"2013","journal-title":"Arthritis Rheum"},{"key":"15","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1002\/art.41012","article-title":"The efficacy, tolerability, and joint safety of fasinumab in osteoarthritis pain: a phase IIb\/III double-blind, placebo-controlled, randomized clinical trial.","volume":"7","author":"Geba","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"16","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"33","author":"Altman","year":"2009","journal-title":"BMJ"},{"key":"17","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.clinthera.2006.03.008","article-title":"A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.","volume":"2","author":"Galer","year":"2006","journal-title":"Clin Ther"},{"key":"18","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1185\/030079903125002469","article-title":"A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis.","volume":"1","author":"Ozturk","year":"2003","journal-title":"Curr Med Res Opin"},{"key":"19","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.joca.2007.05.022","article-title":"A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis.","volume":"1","author":"Reicin","year":"2007","journal-title":"Osteoarthritis Cartilage"},{"key":"20","doi-asserted-by":"publisher","first-page":"239501","DOI":"10.1155\/2011\/239501","article-title":"A phase IIIb, multicentre, randomised, parallel-group, placebo-controlled, double-blind study to investigate the efficacy and safety of OROS hydromorphone in subjects with moderate-to-severe chronic pain induced by osteoarthritis of the hip or the knee.","volume":"201","author":"Richarz","year":"2011","journal-title":"Pain Res Treat"},{"key":"21","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1185\/03007995.2014.949646","article-title":"A randomized, double-blind, placebo-controlled 12 week trial of acetaminophen extended release for the treatment of signs and symptoms of osteoarthritis.","volume":"3","author":"Frustaci","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.clinthera.2008.01.016","article-title":"Analgesic effectiveness of celecoxib and diclofenac in patients with osteoarthritis of the hip requiring joint replacement surgery: a 12-week, multicenter, randomized, double-blind, parallel-group, double-dummy, noninferiority study.","volume":"3","author":"Lowry","year":"2008","journal-title":"Clin Ther"},{"key":"23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/030097401750065265","article-title":"Celecoxib versus diclofenac in the management of osteoarthritis of the knee.","volume":"3","author":"Geis","year":"2001","journal-title":"Scand J Rheumatol"},{"key":"24","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.3899\/jrheum.081316","article-title":"Diclofenac sodium gel in patients with primary hand osteoarthritis: a randomized, double-blind, placebo-controlled trial.","volume":"3","author":"Zacher","year":"2009","journal-title":"J Rheumatol"},{"key":"25","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1503\/cmaj.1031793","article-title":"Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial.","volume":"17","author":"Shainhouse","year":"2004","journal-title":"CMAJ"},{"key":"26","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1185\/03007995.2014.946123","article-title":"Efficacy and safety of low-dose submicron diclofenac for the treatment of osteoarthritis pain: a 12 week, phase 3 study.","volume":"3","author":"Young","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"27","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/1756-185X.12667","article-title":"Efficacy and safety of nonsteroidal anti-inflammatory drugs in Asian patients with knee osteoarthritis: summary of a randomized, placebo-controlled study.","volume":"1","author":"Bao","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"28","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1080\/03007995.2017.1417245","article-title":"Efficacy and safety of twice daily sustained-release paracetamol formulation for osteoarthritis pain of the knee or hip: a randomized, double-blind, placebo-controlled, twelve-week study.","volume":"3","author":"Moreira","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"29","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1177\/147323001204000414","article-title":"Efficacy and tolerability of celecoxib versus naproxen in patients with osteoarthritis of the knee: a randomized, double-blind, double-dummy trial.","volume":"4","author":"Sands","year":"2012","journal-title":"J Int Med Res"},{"key":"30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1185\/030079902125000282","article-title":"Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial.","volume":"1","author":"Ng","year":"2002","journal-title":"Curr Med Res Opin"},{"key":"31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/0300060516673707","article-title":"Efficacy of celecoxib versus ibuprofen for the treatment of patients with osteoarthritis of the knee: a randomized double-blind, non-inferiority trial.","volume":"4","author":"Zhou","year":"2017","journal-title":"J Int Med Res"},{"key":"32","first-page":"2384","article-title":"Efficacy of topical diclofenac diethylamine gel in osteoarthritis of the knee.","volume":"3","author":"Elkik","year":"2005","journal-title":"J Rheumatol"},{"key":"33","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1185\/03007995.2014.955169","article-title":"Etoricoxib in the treatment of Korean patients with osteoarthritis in a double-blind, randomized controlled trial.","volume":"3","author":"Shim","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"34","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/MJT.0b013e3181cec307","article-title":"Tramadol hydrochloride extended-release once-daily in the treatment of osteoarthritis of the knee and\/or hip: a double-blind, randomized, dose-ranging trial.","volume":"1","author":"Fleming","year":"2011","journal-title":"Am J Ther"},{"key":"35","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1136\/ard.2006.059162","article-title":"Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis.","volume":"6","author":"Reicin","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"36","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1185\/030079906X115595","article-title":"Extended-release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double-blind, placebo-controlled clinical trial.","volume":"2","author":"Vorsanger","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"37","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1136\/ard.2005.040519","article-title":"Greater reduction of knee than hip pain in osteoarthritis treated with naproxen, as evaluated by WOMAC and SF-36.","volume":"6","author":"Lohmander","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"38","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1533-2500.2012.00555.x","article-title":"Results of a double-blind, placebo-controlled, fixed-dose assessment of once-daily OROS\u00ae hydromorphone ER in patients with moderate to severe pain associated with chronic osteoarthritis.","volume":"1","author":"Thipphawong","year":"2013","journal-title":"Pain Pract"},{"key":"39","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1136\/ard.2003.017236","article-title":"Paracetamol in osteoarthritis of the knee.","volume":"6","author":"Dougados","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"40","first-page":"E749","article-title":"Randomized clinical trial evaluating transdermal ibuprofen for moderate to severe knee osteoarthritis.","volume":"1","author":"Carter","year":"2013","journal-title":"Pain Physician"},{"key":"41","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.joca.2006.10.008","article-title":"Three-month efficacy and safety of acetaminophen extended-release for osteoarthritis pain of the hip or knee: a randomized, double-blind, placebo-controlled study.","volume":"1","author":"Schweinle","year":"2007","journal-title":"Osteoarthritis Cartilage"},{"key":"42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.joca.2008.05.018","article-title":"A 4-week randomized study of acetaminophen extended-release vs rofecoxib in knee osteoarthritis.","volume":"1","author":"Altman","year":"2009","journal-title":"Osteoarthritis Cartilage"},{"key":"43","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1001\/archinte.160.12.1781","article-title":"A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib\/ibuprofen comparator study group.","volume":"16","author":"Ehrich","year":"2000","journal-title":"Arch Intern Med"},{"key":"44","first-page":"2438","article-title":"Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib osteoarthritis pilot study group.","volume":"2","author":"Gertz","year":"1999","journal-title":"J Rheumatol"},{"key":"45","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1002\/1529-0131(200005)43:5<978::AID-ANR4>3.0.CO;2-0","article-title":"Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib phase III protocol 035 study group.","volume":"4","author":"Daniels","year":"2000","journal-title":"Arthritis Rheum"},{"key":"46","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/j.joca.2014.10.003","article-title":"A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee.","volume":"2","author":"Marks","year":"2015","journal-title":"Osteoarthritis Cartilage"},{"key":"47","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/pm\/pnw262","article-title":"Efficacy and safety of tanezumab on osteoarthritis knee and hip pains: a meta-analysis of randomized controlled trials.","volume":"1","author":"Zha","year":"2017","journal-title":"Pain Med"},{"key":"48","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.joca.2016.01.135","article-title":"Comparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review.","volume":"2","author":"Losina","year":"2016","journal-title":"Osteoarthritis Cartilage"},{"key":"49","unstructured":"Higgins, Green. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. https:\/\/training.cochrane.org\/handbook\/archive\/v5.1\/."},{"key":"50","unstructured":"Higgins, Deeks, Altman. Chapter 16: Special topics in statistics. In: Higgins, Green (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. https:\/\/training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"51","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous comparison of multiple treatments: combining direct and indirect evidence.","volume":"33","author":"Higgins","year":"2005","journal-title":"BMJ"},{"key":"52","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.jclinepi.2009.08.025","article-title":"Mixed treatment comparison analysis provides internally coherent treatment effect estimates based on overviews of reviews and can reveal inconsistency.","volume":"6","author":"Ades","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"53","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons.","volume":"2","author":"Ades","year":"2004","journal-title":"Stat Med"},{"key":"54","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/s0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials.","volume":"5","author":"Walter","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00019053-200624010-00001","article-title":"Bayesian methods for evidence synthesis in cost-effectiveness analysis.","volume":"2","author":"Lu","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"56","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2165\/00019053-200826090-00006","article-title":"Use of indirect and mixed treatment comparisons for technology assessment.","volume":"2","author":"Abrams","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"57","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","article-title":"General Methods for Monitoring Convergence of Iterative Simulations.","volume":"7","author":"Gelman","year":"1998","journal-title":"Journal of Computational and Graphical Statistics"},{"key":"58","doi-asserted-by":"publisher","first-page":"c4675","DOI":"10.1136\/bmj.c4675","article-title":"Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis.","volume":"34","author":"Trelle","year":"2010","journal-title":"BMJ"},{"key":"59","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial.","volume":"6","author":"Ioannidis","year":"2011","journal-title":"J Clin Epidemiol"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.202232","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,18]],"date-time":"2024-08-18T13:25:45Z","timestamp":1723987545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.202232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,3]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,15]]}},"alternative-id":["202232","33293475"],"URL":"https:\/\/doi.org\/10.18632\/aging.202232","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,3]]}}}